Concert Pharmaceuticals - CNCE Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Concert Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CNCE shares.
View CNCE analyst ratings or view top-rated stocks.

3 brokerages have issued 1-year price targets for Concert Pharmaceuticals' shares. Their CNCE share price forecasts range from $9.00 to $17.00. On average, they predict the company's share price to reach $12.00 in the next twelve months. This suggests a possible upside of 78.6% from the stock's current price.
View analysts price targets for CNCE or view top-rated stocks among Wall Street analysts.

Concert Pharmaceuticals' stock was trading at $3.15 at the beginning of 2022. Since then, CNCE stock has increased by 113.3% and is now trading at $6.72.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our CNCE earnings forecast.

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) issued its quarterly earnings results on Tuesday, November, 9th. The biotechnology company reported ($0.78) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.81) by $0.03. The biotechnology company had revenue of $0.54 million for the quarter, compared to analyst estimates of $0.25 million. Concert Pharmaceuticals had a negative trailing twelve-month return on equity of 116.27% and a negative net margin of 245.72%. During the same period last year, the company posted ($0.60) earnings per share.

1 employees have rated Concert Pharmaceuticals Chief Executive Officer Roger Tung on Glassdoor.com. Roger Tung has an approval rating of 100% among the company's employees. This puts Roger Tung in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Concert Pharmaceuticals investors own include Gilead Sciences (GILD), Eiger BioPharmaceuticals (EIGR), Exelixis (EXEL), ACADIA Pharmaceuticals (ACAD), Nektar Therapeutics (NKTR), TG Therapeutics (TGTX), Celldex Therapeutics (CLDX), Amicus Therapeutics (FOLD), Global Blood Therapeutics (GBT) and Intel (INTC).

Concert Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNCE."

Concert Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Nantahala Capital Management LLC (4.57%), Millennium Management LLC (3.42%), Renaissance Technologies LLC (2.55%), Assenagon Asset Management S.A. (1.51%), AWM Investment Company Inc. (1.39%) and Connor Clark & Lunn Investment Management Ltd. (0.83%). Insiders that own company stock include Heek Christi Van, James V Cassella, Jeffrey A Munsie, Marc A Becker, Nancy Stuart, Roger D Tung and Thomas G Auchincloss.
View institutional ownership trends.

Shares of CNCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CNCE stock can currently be purchased for approximately $6.72.

Concert Pharmaceuticals (NASDAQ:CNCE) has a market capitalization of $244.14 million and generates $32.58 million in revenue each year. The biotechnology company earns $-80,050,000.00 in net income (profit) each year or ($3.41) on an earnings per share basis.

Concert Pharmaceuticals' mailing address is 65 HAYDEN AVENUE SUITE 3000N, LEXINGTON MA, 02421. The official website for the company is www.concertpharma.com. The biotechnology company can be reached via phone at (781) 860-0045, via email at ir@concertpharma.com, or via fax at 302-636-5454.